MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pantothenate kinase-associated neurodegenetration(PKAN)"

  • 2019 International Congress

    Longitudinal analysis of disease progression in a large PKAN cohort in the Dominican Republic

    C. Muniz, S. Baser, R. Ericson, M. Santana Jimenez, C. Bass, F. Middleton (Santo Domingo, Dominican Republic)

    Objective: To analyze the rate of disease progression of PKAN over a 12 year period in 37 patients with genetically-confirmed PKAN in the Dominican Republic.…
  • 2019 International Congress

    Deep Brain Stimulation for atypical tremors secondary to Neuroferritinopathy: Single center experience

    S. Chandra, J. Randhawa, M. Schiess (Houston, TX, USA)

    Objective: To describe the clinical response to deep brain stimulation. Background: Neuroferritinopathy is a neurodegenerative disease in which mutations in the ferritin light polypeptide (FTL)…
  • 2019 International Congress

    Dystonic opisthotonus: A clinical clue to neurodegeneration with brain iron accumulation in young adults

    S. Mehta, V. Lal (Chandigarh, India)

    Objective: To describe the diagnostic value of dystonic opisthotonus as a clinical clue towards a diagnosis of neurodegeneration with brain iron accumulation. Background: Differential diagnosis…
  • 2019 International Congress

    Deep Brain Stimulation (DBS) in Pantothenate Kinase-Associated Neurodegeneration (PKAN): An Experience in a Thai Patient

    P. Termsarasab, P. Boonkongchuen, T. Pulkes, O. Trachoo, A. Boongird (Bangkok, Thailand)

    Objective: To report a patient with PKAN whose dystonia improved with bilateral pallidal (GPi) DBS. Background: The benefits of GPi DBS are well-recognized in primary…
  • 2019 International Congress

    Pantothenate kinase-associated neurodegeneration in Tunisian families

    H. Benrhouma, I. Kraoua, H. Klaa, A. Rouissi, EM. Valente, I. Benyoussef Turki (Tunis, Tunisia)

    Objective: To describe clinical features, imaging and genetic findings of 6 Tunisian families diagnosed with PKAN. Background: Pantothenate kinase-associated neurodegeneration (PKAN) is an autosomal recessive…
  • 2019 International Congress

    Spastic ataxia and pseudo eye-of-the-tiger sign in a familiy with a novel compound heterozygous AFG3L2 mutations

    G. Buda, S. Vishnopolska, J. Oliveri, F. Olivieri, G. Biagioli, L. Miquelini, A. Pellene, M. Marti, C. Calandra (Buenos Aires, Argentina)

    Objective: Identify by exome sequencing (ES) the underlying etiology of spastic ataxia and pseudo eye-of-the-tiger sign (EOT) in 4 siblings. Background: The EOT is a…
  • 2019 International Congress

    A Systems Approach Model for Pantothenate Kinase-Associated Neurodegeneration (PKAN)- Assessment and Treatment

    S. Baser, C. Muniz, F. Middleton, R. Ericson, C. Bass (Pittsburgh, PA, USA)

    Objective: Propose a new systems approach model for PKAN, investigate treatment, and establish biologic and genetic markers. Background: PKAN is a recessive, rare, inborn error…
  • 2019 International Congress

    Distinct phenotypic expression in a large PKAN cohort in the Dominican Republic

    S. Baser, C. Muniz, F. Middleton, R. Ericson, M. Santana Jimenez, C. Bass (Pittsburgh, PA, USA)

    Objective: Analysis of a large genetically homogenous PKAN population, assessing demographics, clinical features, and rating scales to characterize observed phenotypic heterogeneity. Background: PKAN is an…
  • 2018 International Congress

    The FOsmetpantotenate Replacement Therapy (FORT) Pivotal Trial: Utilization of a Novel Primary Efficacy Outcome in Patients with Pantothenate Kinase-Associated Neurodegeneration

    F. Greblikas, M. Escolar, T. Klopstock, R. Marshall, B. Perez, S. Tuller, A. Videnovic (San Diego, CA, USA)

    Objective: To describe the methodology and novel primary efficacy outcome measure in the ongoing pivotal FORT trial in patients with pantothenate kinase-associated neurodegeneration (PKAN). Background:…
  • 2018 International Congress

    Atypical presentation of PANK2 mutation: A case report

    M. Sousa, R. Varela, A. Morgadinho, C. Januário (Coimbra, Portugal)

    Objective: To describe an atypical presentation of a PANK2 mutation. Background: PKAN (Pantothenate-Kinase-Associated Neurodegeneration) is the most common NBIA (Neurodegeneration with brain iron accumulation) disorder,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley